The OSU Multiple Sclerosis Center is enrolling patients into a clinical trial that are ready for Rebif® therapy. Participating patients will be randomly assigned to receive either Rebif® therapy alone or in combination with CellCept®. This is a single center trial looking to add CellCept therapy to the early treatment of relapsing remitting multiple sclerosis. Eligible patients will not have had steroids in the last 30 days and never have taken Imuran, methotrexate, mitoxantrone cyclophosphamide or any other immunosuppressive therapy for their multiple sclerosis.
For more information or to enroll in this study, please contact Lisa Hafer in the Department of Neurology at 614-293-7877, or
e-mail Lisa.Hafer@osumc.edu.